» Articles » PMID: 17185075

Does Cancer Risk Affect Health-related Quality of Life in Patients with Barrett's Esophagus?

Overview
Date 2006 Dec 23
PMID 17185075
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Health-related quality of life is decreased in patients with GERD and Barrett's esophagus (BE).

Objective: To determine whether time-tradeoff (TTO) values would differ in patients with BE when patients were asked to trade away the potential risk of esophageal adenocarcinoma rather than chronic heartburn symptoms.

Design: A prospective clinical trial.

Patients: Subjects with biopsy-proven BE.

Interventions: Custom-designed computer program to elicit health-state utility values, quality of life in reflux and dyspepsia (QOLRAD), and Medical Outcomes Survey short form-36 surveys.

Main Outcome Measurements: TTO utility values for the annual cancer-risk-associated current health state and for hypothetical scenarios of dysplasia and esophageal cancer.

Results: We studied 60 patients in the cancer-risk cohort (57 men, 92% veteran; mean age [standard deviation; SD], 65 years [11 years], mean GERD duration 17 years [12 years]). The heartburn cohort included 40 patients with GERD and BE with TTO values derived for GERD symptoms. The mean (SD) utility for nondysplastic BE was 0.91 (0.13) compared with 0.90 (0.12) for the heartburn cohort (P = .7). The mean utility values were significantly lower for scenarios of low-grade dysplasia (0.85 [0.12], P = .02) and high-grade dysplasia (0.77 [0.14], P < .005). The mean TTO was 0.67 (0.19) for the scenario of esophageal cancer. There was no correlation between the utility scores and the disease-specific survey scores.

Limitations: TTO values were hypothetical for states of dysplasia and cancer.

Conclusions: TTO utility values based on heartburn symptoms or annual risk of cancer in patients with nondysplastic BE are roughly equivalent. However, TTO utility values are significantly lower for health states with increasing cancer risks.

Citing Articles

Factors influencing the cost-effectiveness of radiofrequency ablation for Barrett's esophagus with low-grade dysplasia in Australia.

Caush L, Church J, Goodall S, Lord R Dis Esophagus. 2024; 38(1).

PMID: 39498762 PMC: 11705073. DOI: 10.1093/dote/doae095.


Quality of life, clinical outcomes and cost utilization of endoscopic therapy in patients with Barrett's esophagus and early esophageal cancer-an 8-year Canadian experience.

David J, Woo M, Congly S, Andrews C, Jeyalingam T, Belletrutti P J Can Assoc Gastroenterol. 2024; 7(5):368-375.

PMID: 39416720 PMC: 11477975. DOI: 10.1093/jcag/gwae018.


Quality of life measures in dysplastic Barrett's oesophagus are comparable to patients with non-dysplastic Barrett's oesophagus and do not improve after endoscopic therapy.

Ratcliffe E, Britton J, Heal C, Keld R, Murgatroyd M, Willert R BMJ Open Gastroenterol. 2023; 10(1).

PMID: 37041020 PMC: 10105999. DOI: 10.1136/bmjgast-2022-001091.


How are we measuring health-related quality of life in patients with a Barrett Esophagus? A systematic review on patient-reported outcome measurements.

Loon M, Stoker A, Nieuwkerk P, Curvers W, Schoon E Qual Life Res. 2021; 31(6):1639-1656.

PMID: 34748137 PMC: 9098608. DOI: 10.1007/s11136-021-03009-7.


Economic evaluation of Cytosponge®-trefoil factor 3 for Barrett esophagus: A cost-utility analysis of randomised controlled trial data.

Swart N, Maroni R, Muldrew B, Sasieni P, Fitzgerald R, Morris S EClinicalMedicine. 2021; 37:100969.

PMID: 34195582 PMC: 8225801. DOI: 10.1016/j.eclinm.2021.100969.